Moderators:
Search This Board: 
Created: 02/27/2005 04:26:50 AM - Followers: 53 - Board type: Free - Posts Today: 0

Results From SOLOIST and SCORED Outcomes Studies Presented at Late-Breaking Science Session of American Heart Association Scientific Sessions and Published in The New England Journal of Medicine

 
 
Lexicon Pharmaceuticals, Inc.
Mon, November 16, 2020, 10:02 PM EST
 
 

Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies

THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.

In the SOLOIST study, the primary endpoint was achieved with a hazard ratio (HR) of 0.67 (p<0.001) in people with type 2 diabetes and a recent hospitalization for worsening heart failure. In the SCORED study, the primary endpoint was achieved with a hazard ratio of 0.74 (p<0.001) in people with type 2 diabetes and chronic kidney disease with an estimated glomerular filtration rate (eGFR) of 25 to 60 ml/minute per 1.73 m² of body-surface area.

 

The key results from SOLOIST and SCORED were presented today at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” and “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.” The articles may be accessed at www.nejm.org.

“Cardiovascular disease continues to be a leading cause of death in people with type 2 diabetes,” said Deepak L. Bhatt, M.D., M.P.H., executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital and a professor of medicine at Harvard Medical School and study chair and lead author for the NEJM publications of the SOLOIST and SCORED results. “SOLOIST demonstrates that early, in-hospital initiation of sotagliflozin in patients with worsening heart failure significantly reduces subsequent cardiovascular events, an effect that was consistent across groups with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). SCORED demonstrates that sotagliflozin significantly reduces heart failure events in a patient population with stage 3 and 4 chronic kidney disease and cardiovascular risk. Both studies add to the evidence that SGLT2 inhibition should be standard of care in heart failure, and the SCORED data reflecting a reduction in myocardial infarction and stroke and better glucose control in CKD patients suggest potential benefits from the dual SGLT1 and SGLT2 mechanism of this particular agent.”

 
 
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#715
Awesome. For real. BooDog 06/29/2022 05:08:00 PM
#714
“We expect that the new joint guidelines issued BooDog 04/19/2022 06:24:27 AM
#713
Very interesting intraday recovery. News after close? BooDog 01/14/2022 04:01:40 PM
#712
What do I dislike more than bleeders? BooDog 01/13/2022 12:52:12 PM
#711
Might be my last add here, $3.58. BooDog 01/12/2022 10:28:16 AM
#710
If this works out my 3.48's may see BooDog 01/06/2022 01:05:20 PM
#709
Gap from last August fills 3.48. I'll bite. BooDog 01/05/2022 03:34:07 PM
#708
VP, HUMAN RESOURCES form 3 filed. Initial statement. BooDog 01/05/2022 09:01:17 AM
#707
Don't let the price action fool you, play BooDog 01/03/2022 12:45:04 PM
#706
LXRX 4.99 Golden Cross in progress. BooDog 11/17/2021 12:44:32 PM
#705
Should have remembered what earnings do in this BooDog 11/04/2021 03:38:08 PM
#704
Picking up some momentum! Great!! BooDog 11/03/2021 03:11:48 PM
#703
Thanks Chupacabra Gigante!!! Yes, looking very good BooDog 11/01/2021 11:01:06 AM
#702
200 DMA 5.32, 50 DMA 4.94. With a BooDog 10/29/2021 11:59:30 AM
#701
Boo Dog Chupacabra Gigante 10/26/2021 04:11:57 PM
#700
This just may get interesting. Let's see BooDog 10/21/2021 03:56:54 PM
#699
Small bite here at $5. Next buy around BooDog 10/19/2021 12:17:57 PM
#698
Did take a few off 6.23. Looking BooDog 10/14/2021 11:18:48 AM
#697
Form 3's building their positions. I'm thinking BooDog 10/08/2021 02:11:59 PM
#696
Didn't think LXRX would push through. New BooDog 10/07/2021 03:46:49 PM
#695
Cramer said 5.90 lol. See if it BooDog 10/06/2021 03:47:22 PM
#694
Big things are happening for LXRX imo. BooDog 08/30/2021 01:01:14 PM
#693
But they have not one piece sold in Logon26 08/30/2021 12:21:22 PM
#692
This is excellent news. Lexicon Welcomes New ESC BooDog 08/30/2021 07:08:19 AM
#691
Couldn't stop myself, locked in some green here. 4.50"s. BooDog 08/27/2021 01:40:52 PM
#690
Sweet! BooDog 08/27/2021 01:19:38 PM
#689
Back over $4. Looking pretty imo. Low BooDog 08/25/2021 12:35:19 PM
#688
ACTIVE POSITIONS HOLDERS SHARES BooDog 08/17/2021 01:08:25 PM
#687
Wouldn't be surprised to see this back over $6. BooDog 07/30/2021 02:09:53 PM
#686
Been munching some of these dips. BooDog 07/28/2021 10:46:26 AM
#685
Added 3.98 today. BooDog 07/06/2021 03:54:02 PM
#684
Mine. I've been waiting forever for this BooDog 07/02/2021 12:46:50 PM
#683 Many predict 15-20 relatively short term if they Guzzi62 01/15/2021 05:47:57 AM
#682 * * $LXRX Video Chart 01-14-2021 * * ClayTrader 01/14/2021 04:26:51 PM
#681 How high can this go? joro44 01/14/2021 02:22:44 PM
#680 Yes a very good day, I am keeping Guzzi62 01/14/2021 11:58:52 AM
#679 LXRX NEWS Lexicon Pharmaceuticals Provides Regulatory Update on BooDog 01/14/2021 11:57:29 AM
#678 Liking the action here!! BooDog 01/08/2021 03:39:13 PM
#677 Skimmed a few off @ 3.60. Looks BooDog 12/31/2020 11:23:17 AM
#676 LXRX Golden cross alert BooDog 12/31/2020 07:50:34 AM
#675 Gosh. What is this ipo_dude 12/21/2020 10:02:20 AM
#674 ?? glad I'm not the only one simmons420 12/17/2020 05:11:42 AM
#673 Took a few more under $3. Why BooDog 12/16/2020 06:09:31 PM
#672 Here's the science with AC Bioscience. They BooDog 12/16/2020 04:28:15 PM
#671 Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience BooDog 12/16/2020 04:15:19 PM
#670 Added 3.13. BooDog 12/16/2020 04:13:04 PM
#669 So BCDA had an offering too and it ipo_dude 12/15/2020 09:15:25 PM
#668 I should have added that if they get BooDog 12/11/2020 12:19:11 PM
#667 Citigroup setting a price target of $6 was BooDog 12/11/2020 11:36:14 AM
#666 Do not understand the 3.20 at all. Just joro44 12/11/2020 10:06:53 AM
Post Subject